摘要
目的探讨慢性乙肝(CHB)患者停药后复发再次应用恩替卡韦治疗的疗效和安全性。方法选取我院2013年1月~2019年1月停用恩替卡韦后复发的60例CHB患者为观察组,同期选取初治的60例CHB患者作为对照组,均在护肝、降酶药物的治疗基础上给予恩替卡韦片治疗,观察两组患者的治疗前和治疗24周后的ALT、AST水平,对两组患者治疗24周后的HBeAg转阴率、HBV-DNA转阴率、临床总有效率和不良反应发生率进行比较。结果治疗前,两组的ALT、AST水平比较,差异无统计学意义(P>0.05);治疗24周后,两组的ALT、AST水平均明显下降,对照组的ALT水平显著低于观察组,差异有统计学意义(P<0.05);而两组AST水平比较,差异无统计学意义(P>0.05);治疗24周后,两组的HBeAg转阴率、HBV-DNA转阴率、临床总有效率和不良反应发生率比较,差异无统计学意义(P>0.05)。结论恩替卡韦对停药后再次复发的CHB患者具有较好的有效性和安全性,但肝功能恢复较为缓慢,患者仍需加强护肝意识,规范合理用药。
Objective To explore the efficacy and safety of entecavir in patients with chronic hepatitis B(CHB)with relapse after withdrawal of drugs.Methods 60 patients with CHB who relapsed after entecavir was withdrawn and treated in our hospital from January 2013 to January 2019 were selected as the observation group,and 60 CHB patients with initial treatment were selected as the control group at the same time.Entecavir tablets were given on the basis of enzyme-reducing and liver protection treatment.The levels of alanine aminotransferase(ALT)and aspartate aminotransferase(AST)before and after 24 weeks of treatment were observed in the two groups;the negative conversion ratio of hepatitis Be antigen(HBeAg)and hepatitis B virus deoxyribonucleic acid(HBV-DNA),total clinical effective rate,and incidence of adverse reactions were compared between the two groups.Results Before treatment,there was no significant difference in the levels of ALT and AST between the two groups(P>0.05);after 24 weeks of treatment,the levels of ALT and AST in the two groups were significantly decreased,and the ALT levels in the control group were significantly lower than those in the observation group,and the differences were statistically significant(P<0.05);while there was no difference in AST levels between the two groups(P>0.05).After 24 weeks of treatment,there was no significant difference in the negative conversion ratio of HBeAg and HBV-DNA,total clinical effective rate,and incidence of adverse reactions between the two groups(P>0.05).Conclusion Entecavir is effective and safe for patients with CHB who relapses after withdrawal of drugs.However,the liver function recovery is relatively slow.It is necessary to strengthen patients’awareness of liver protection and standardize rational medication.
作者
刘贵章
冯霞
许静
李声方
夏琴
LIU Guizhang;FENG Xia;XU Jing;LI Shengfang;XIA Qin(Department of Infectious Diseases,Donghua Hospital,Guangdong,Dongguan 523110,China)
出处
《中国医药科学》
2020年第8期50-52,59,共4页
China Medicine And Pharmacy
基金
广东省东莞市社会科技发展(一般)项目(201950715046916)。
关键词
恩替卡韦
慢性乙肝
停药后复发
有效性
安全性
Entecavir
Chronic hepatitis B
Relapse after withdrawal
Effectiveness
Safety
